Brokerages Set Aquinox Pharmaceuticals, Inc. (AQXP) PT at $20.75

Shares of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $22.25.

A number of research firms recently issued reports on AQXP. Zacks Investment Research raised Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Thursday. Canaccord Genuity set a $22.00 target price on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. BidaskClub raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. ValuEngine raised shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, May 9th.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Aquinox Pharmaceuticals, Inc. (AQXP) PT at $20.75” was posted by Rincon Hill News and is the property of of Rincon Hill News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://rinconhillneighbors.org/2017/08/12/aquinox-pharmaceuticals-inc-aqxp-receives-average-rating-of-hold-from-analysts-updated.html.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded up 0.53% during midday trading on Friday, reaching $13.17. The company had a trading volume of 28,620 shares. Aquinox Pharmaceuticals has a 1-year low of $8.76 and a 1-year high of $19.97. The company’s market capitalization is $308.48 million. The firm has a 50-day moving average of $14.49 and a 200 day moving average of $15.46.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59). On average, equities research analysts forecast that Aquinox Pharmaceuticals will post ($2.15) EPS for the current year.

In related news, insider David Main sold 15,625 shares of Aquinox Pharmaceuticals stock in a transaction on Monday, June 5th. The shares were sold at an average price of $13.26, for a total value of $207,187.50. Following the transaction, the insider now owns 77,530 shares in the company, valued at approximately $1,028,047.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Aquinox Pharmaceuticals by 6.6% in the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after buying an additional 17,455 shares during the last quarter. Northern Trust Corp boosted its stake in Aquinox Pharmaceuticals by 3.3% in the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock worth $1,171,000 after buying an additional 2,691 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Aquinox Pharmaceuticals during the second quarter worth $874,000. Archon Partners LLC boosted its stake in Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after buying an additional 5,500 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares during the last quarter. 98.32% of the stock is currently owned by institutional investors and hedge funds.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.